Health
Newer Type 2 diabetes medications could reduce kidney, heart disease risks – News-Medical.Net
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Reviewed by Emily Henderson, B.Sc.Sep 28 2020
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Based on analyses of the clinical trials through March 2020, a group of leading experts in diabetes, heart failure, kidney disease and cardiometabolic disease believe the medicines should be considered for people with CKD and…
-
Noosa News18 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General18 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News10 hours agoNew playground equipment encourages children to learn through ‘risky play’
-
General7 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania